Last reviewed · How we verify
NCT05910697
Clinical Utility of MyProstateScore 2.0 P2
NA trial testing MyProstateScore 2.0 Results in Prostate Cancer in 142 participants. Terminated before completion.
18 October 2023
Quick facts
| Lead sponsor | Qure Healthcare, LLC |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 142 |
| Start date | 31 March 2023 |
| Primary completion | 18 October 2023 |
| Estimated completion | 18 October 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MyProstateScore 2.0 Results
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Qure Healthcare, LLC — full company profile →
Who can join
Eligibility, any sex, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an extension of an ongoing study. Preliminary results from the ongoing study indicate that the MyProstateScore 2.0 (MPS 2.0) Test is significantly improving early diagnosis of prostate cancer. This extension will allow us to ask the study participants in the ongoing study to share patient-level data for chart abstraction. The specific purpose of this study is to generate high-quality real-world data on the clinical utility of LynxDx's new MPS 2.0 test.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05910697
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Qure Healthcare, LLC trials
Trials by the same sponsor.
- NCT07099001 — Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay · NA · completed
- NCT05702385 — Clinical Utility Study for Exo-PDAC · NA · withdrawn
- NCT05603299 — Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test · NA · withdrawn
- NCT05525806 — Clinical Utility Study for MyProstateScore+ · NA · completed
- NCT05658653 — Clinical Utility of CDMT Among VillageMD Providers · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05910697 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qure Healthcare, LLC
- Last refreshed: 15 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05910697.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing